Inogen, Inc. (NASDAQ:INGN) Shares Bought by Quadrature Capital Ltd

Quadrature Capital Ltd raised its holdings in Inogen, Inc. (NASDAQ:INGN) by 106.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 31,071 shares of the medical technology company’s stock after acquiring an additional 16,017 shares during the quarter. Quadrature Capital Ltd owned 0.13% of Inogen worth $171,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in INGN. Kent Lake Capital LLC acquired a new position in shares of Inogen during the 3rd quarter worth $2,418,000. Federated Hermes Inc. raised its stake in shares of Inogen by 347.2% during the 4th quarter. Federated Hermes Inc. now owns 265,485 shares of the medical technology company’s stock worth $1,458,000 after buying an additional 206,125 shares during the last quarter. Meros Investment Management LP raised its stake in shares of Inogen by 14.9% during the 3rd quarter. Meros Investment Management LP now owns 589,604 shares of the medical technology company’s stock worth $3,078,000 after buying an additional 76,294 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Inogen by 26.3% during the 4th quarter. Assenagon Asset Management S.A. now owns 285,176 shares of the medical technology company’s stock worth $1,566,000 after buying an additional 59,446 shares during the last quarter. Finally, Barclays PLC raised its stake in shares of Inogen by 644.6% during the 3rd quarter. Barclays PLC now owns 49,106 shares of the medical technology company’s stock worth $257,000 after buying an additional 42,511 shares during the last quarter. Institutional investors and hedge funds own 89.94% of the company’s stock.

Inogen Trading Up 2.6 %

Shares of INGN stock opened at $7.97 on Friday. The firm has a 50-day moving average price of $7.94 and a 200 day moving average price of $7.26. Inogen, Inc. has a twelve month low of $4.13 and a twelve month high of $11.98. The company has a market capitalization of $187.93 million, a price-to-earnings ratio of -1.92 and a beta of 1.07.

Inogen (NASDAQ:INGN) last posted its quarterly earnings results on Tuesday, May 7th. The medical technology company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.14. The company had revenue of $78.03 million during the quarter, compared to analysts’ expectations of $73.67 million. Inogen had a negative return on equity of 42.87% and a negative net margin of 30.07%. The firm’s revenue was up 8.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.63) EPS. As a group, research analysts predict that Inogen, Inc. will post -2.2 earnings per share for the current year.

Insider Buying and Selling at Inogen

In other Inogen news, EVP Jason Somer sold 10,000 shares of Inogen stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $8.56, for a total value of $85,600.00. Following the completion of the sale, the executive vice president now owns 4,452 shares in the company, valued at approximately $38,109.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.99% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Inogen in a research note on Wednesday, May 8th. StockNews.com raised shares of Inogen from a “sell” rating to a “hold” rating in a research note on Monday. Finally, Stifel Nicolaus boosted their target price on shares of Inogen from $6.00 to $7.00 and gave the company a “hold” rating in a research note on Wednesday, May 8th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $7.00.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.